| StockFetcher Forums · Stock Picks and Trading · Pattern Watching | << 1 2 3 4 5 ... 20 >>Post Follow-up |
| Nobody 404 posts msg #156334 - Ignore Nobody modified |
3/30/2021 4:46:05 PM Hi Push5280 I learned that from shillllihs draw indposition(OBV,50) line at .80 draw indposition(OBV,50) line at .20 |
| push5280 201 posts msg #156338 - Ignore push5280 |
3/30/2021 6:55:46 PM Nice! Thanks for sharing, I'll file that away for later! |
| Nobody 404 posts msg #156341 - Ignore Nobody modified |
3/30/2021 11:31:39 PM Any recommendations on determining if being accumulated |
| Nobody 404 posts msg #156346 - Ignore Nobody |
3/31/2021 12:15:23 PM FINIZ showing insider transaction -- |
| Nobody 404 posts msg #156363 - Ignore Nobody modified |
4/1/2021 11:18:04 AM
Biden Clean Energy stuff |
| Nobody 404 posts msg #156364 - Ignore Nobody |
4/1/2021 11:24:46 AM |
| Nobody 404 posts msg #156441 - Ignore Nobody modified |
4/8/2021 2:17:46 PM there we go slow but all good 
|
| Nobody 404 posts msg #156443 - Ignore Nobody modified |
4/8/2021 2:25:47 PM
|
| Nobody 404 posts msg #156446 - Ignore Nobody |
4/8/2021 2:49:28 PM $AMRN Above - from https://www.fool.com/investing/2021/04/01/3-great-stocks-under-10-a-share/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article 1. Amarin -- $6 per share This Irish biotech is my favorite value play right now. The company has an amazing drug, Vascepa, which reduces the risk of major adverse cardiovascular events by 25% in people who are on statin therapy. This is big news, as it suggests a new understanding of heart disease, the No. 1 killer of humans -- namely, that it's not enough to control cholesterol with statins. Vascepa reduces triglycerides (a type of fat in your blood). According to a Harvard study from 2018, by reducing triglycerides, Vascepa succeeded in reducing heart attacks, strokes, and deaths. Why is the stock so cheap? I see two reasons. Number one is the fact that the COVID-19 lockdown has hampered sales growth. Doctors have to be informed about new medical breakthroughs, but that's hard to do in the midst of a lockdown, during which it has been hard to reach doctors. Despite that difficulty, Amarin increased revenue by 43% in 2020. I expect that rate to increase dramatically when the COVID-19 lockdown is over. The main reason the stock is cheap, however, is that a couple of Amarin's patents were invalidated by a trial judge last year. That's opened the door to generic companies offering a version of Vascepa in the U.S., and cast a cloud over the company's growth story. All that doubt has been baked into the share price, and then some. Nonetheless, I expect Vascepa sales to spike in the future. The market opportunity is massive, as an estimated 80 million people in Europe alone have cardiovascular disease. Amarin's patents in the rest of the world remain intact, and the European Commission is now allowing Amarin to market the drug to reduce the risk of cardiovascular events. And the invalidated patents in the U.S. only allow competition in the market to reduce triglycerides, not in the market to improve heart health. In short, Amarin has an approved drug that will save lives, a huge market opportunity, a strong competitive moat, and a price-to-sales (P/S) ratio of 3. For those reasons, I'm bullish. |
| Nobody 404 posts msg #156448 - Ignore Nobody modified |
4/8/2021 3:12:08 PM Eye on Bio 
|
| StockFetcher Forums · Stock Picks and Trading · Pattern Watching | << 1 2 3 4 5 ... 20 >>Post Follow-up |